Shahid Beheshti University of Medical Sciences — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
MLC601Current therapeutic approaches for the treatment of neurodegenerative diseases like Alzheimer disease (AD) offer limited and often transient symptomatic benefits to patients but do not mitigate the insidious loss of neuronal cells. In this trial the investigators will evaluate Efficacy and Tolerability of MLC601 as a neuroprotective in Patients with Mild to Moderate Alzheimer Disease who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.	Alzheimer	Phase 2	Neuroprotection + Traitement symptomatique	Iran	À vérifier
MLC601Current therapeutic approaches for the treatment of neurodegenerative diseases like Alzheimer disease (AD) offer limited and often transient symptomatic benefits to patients but do not mitigate the insidious loss of neuronal cells. In this trial the investigators will evaluate Efficacy and Tolerability of MLC601 as a neuroprotective in Patients with Mild to Moderate Alzheimer Disease who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.	Alzheimer	Phase 2	Neuroprotection + Traitement symptomatique	Iran	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
MLC601	Alzheimer	Phase 2	NCT01696123	Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.